Metropolis Healthcare Intrinsic Value
Metropolis Healthcare (METROPOLIS) median intrinsic value is ₹329.90 from 10 valuation models (range ₹179–₹889), vs current price ₹597.45 — -44.8% downside (Trading Above Calculated Value), margin of safety -81.1%. Check METROPOLIS market value to track the company's total market size over time.
METROPOLIS Valuation Methods Summary — DCF, Graham Number & P/E
Metropolis Healthcare intrinsic value across 10 models vs current price ₹597.45 — upside/downside and value range per method. For current market price and key ratios, visit METROPOLIS share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹179.24 | ₹143.39 - ₹215.09 | -70.0% | EPS: ₹9.84, Sector P/E: 12x |
| Book Value Method | asset | ₹363.10 | ₹326.79 - ₹399.41 | -39.2% | Book Value/Share: ₹363.10, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹329.90 | ₹296.91 - ₹362.89 | -44.8% | Revenue/Share: ₹412.38, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹662.86 | ₹596.57 - ₹729.15 | +10.9% | EBITDA: ₹464.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹889.37 | ₹711.50 - ₹1067.24 | +48.9% | CF Growth: 8.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹179.24 | ₹161.32 - ₹197.16 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹179.24 | ₹161.32 - ₹197.16 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹582.86 | ₹524.57 - ₹641.15 | -2.4% | ROE: 13.4%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹283.53 | ₹255.18 - ₹311.88 | -52.5% | EPS: ₹9.84, BVPS: ₹363.10 |
| Dividend Yield Method | dividend | ₹179.24 | ₹161.32 - ₹197.16 | -70.0% | DPS: ₹5.00, Target Yield: 3.5% |
METROPOLIS Intrinsic Value vs Market Price — All Valuation Models
Metropolis Healthcare fair value range ₹179–₹889 vs current market price ₹597.45 across 10 valuation models. See Metropolis Healthcare P/B ratio trends to compare market price against book value per share.
METROPOLIS Intrinsic Value Analysis — Undervalued or Overvalued?
Metropolis Healthcare median intrinsic value ₹329.90, current price ₹597.45 — Trading Above Calculated Value by 44.8%, margin of safety -81.1%.
What is the intrinsic value of METROPOLIS?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Metropolis Healthcare (METROPOLIS) is ₹329.90 (median value). With the current market price of ₹597.45, this represents a -44.8% variance from our estimated fair value.
The valuation range spans from ₹179.24 to ₹889.37, indicating ₹179.24 - ₹889.37.
Is METROPOLIS undervalued or overvalued?
Based on our multi-method analysis, Metropolis Healthcare (METROPOLIS) appears to be trading above calculated value by approximately 44.8%.
METROPOLIS Financial Health — Key Ratios vs Industry Benchmarks
Metropolis Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.68 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 13.4% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 25.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.81x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
METROPOLIS Cash Flow Quality — Operating & Free Cash Flow
Metropolis Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹351 Cr | ₹241 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹263 Cr | ₹164 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹264 Cr | ₹220 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹247 Cr | ₹247 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹253 Cr | ₹-115 Cr | Positive Operating Cash Flow | 6/10 |